Abstract 3156
Background
LAPTM5 (lysosomal-associated protein transmembrane 5) is a protein that is preferentially expressed in immune cells, and it interacts with the Nedd4 family of ubiquitin ligases. Recent studies in T and B cells identified LAPTM5 as a negative regulator of T and B cell receptor levels at the plasma membrane, but a positive modulator of inflammatory signaling pathways and hence cytokine secretion in macrophages. However, the expression and function of LAPTM5 in ovarian cancer remains undefined.
Methods
LAPTM5 expression in ovarian cancer, benign and normal ovarian tissues was examined by immunohistochemistry. The LAPTM5 mRNA and protein level of OV cells were detected by Q-PCR and Western blotting respectively. Cell apoptosis, migration and invasion changes were observed through high-content screening. The proteins expression involved in epithelial-mesenchymal transition (EMT) and TGF-β mediated signaling pathways was verified by Werstern blotting and immunofluorescence. The role of LAPTM5 on tumorigenesis in vivo was detected by the xenograft model.
Results
Our study showed that in human OV cell lines and tissues, LAPTM5 were significantly induced at both mRNA and protein levels. Furthermore, an OV cell model with downregulated LAPTM5 were established, revealing a significantly alteration of apoptosis. Moreover, analysis of the changes of migration and invasion, showed significant reduced LAPTM5 suppressed cell metastasis. Proteins involved in EMT were strongly altered, which plays a central role in cell metastasis. In addition, phosphorylated ERK1/2, p38 and JNK, key members of mitogen-activated protein kinase (MAPK) family, and phosphorylated Smad2 and Smad3 of Smad signaling pathways mediated by TGF-β regulating OV cells EMT, were strongly decreased. And, LAPTM5 knockdown also inhibited tumorigenesis in xenograft model.
Conclusions
Taken together, our results suggested that LAPTM 5 acts as a positive modulator of MAPK and TGFβ/Smad signaling pathways mediated by TGFβ in OV cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Obstetrics and Gynecology Hospital, Capital Medical University.
Funding
The National Natural Science Foundation of China (grants 81672838), Beijing Municipal Science & Technology Commission (No. Z181100001718193).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract